Group 1 - Dongxing Medical plans to acquire 90% equity of Wuhan Yijiaobao for cash, which is expected to constitute a major asset restructuring [1] - Fosun Pharma's subsidiary plans to transfer 100% equity of Shanghai Cloning, with a transaction value of up to 1.256 billion yuan [1] Group 2 - *ST Songfa's subsidiary signed a shipbuilding contract worth approximately 400-600 million USD for four VLCCs, expected delivery between late 2026 and mid-2027 [3] - Qibin Group obtained financing support of up to 90 million yuan for share repurchase [4] Group 3 - Shapuaisi's shareholder plans to reduce holdings by up to 3% of the company's total shares [5] - *ST Kaixin intends to use up to 310 million yuan for cash management in safe and liquid financial products [6] Group 4 - Junchen Technology's shareholders plan to transfer 2.5% of the company's shares due to personal funding needs [7] - Jingliang Holdings received an administrative regulatory measure from Hainan Securities Regulatory Bureau for improper revenue recognition involving 299 million yuan [7] Group 5 - Tongcheng Holdings received a cash dividend of 24.6643 million yuan from Changsha Bank [9] - Shenyang Chemical appointed Chen Liguo as the new general manager [10] Group 6 - Huaguang Huaneng signed a contract for a 160 million yuan waste heat boiler project [15] - Shuxian Valley's subsidiary completed the re-registration of a health food product [16] Group 7 - Xuanta Pharmaceutical's new specification for a diabetes treatment drug was approved [17] - Panlong Pharmaceutical's application for a pain relief gel patch was accepted by the drug regulatory authority [18] Group 8 - Zhiguang Electric's subsidiary won a procurement contract worth 164 million yuan for a storage system [19] - Chitianhua's production facility resumed operations after maintenance [20] Group 9 - Haitong Development's application for a specific A-share issuance was accepted by the Shanghai Stock Exchange, aiming to raise 210 million yuan [20] - Risheng Technology's shareholders plan to transfer 4.02% of the company's shares [33] Group 10 - Pingmei Shares' controlling shareholder plans a strategic restructuring with Henan Energy Group [35] - Shenghui Integration's controlling shareholder committed not to reduce shareholdings for 12 months [37] Group 11 - Agricultural Bank and Bank of China will no longer establish supervisory boards, with their functions transferred to the audit committees [39][40] - Dongfang Yuhong's subsidiary signed a contract for a seawater pipeline project worth 2.524 billion USD [40][41] Group 12 - Ganfeng Lithium plans to introduce investors for a capital increase of up to 2.5 billion yuan [50] - Hanyu Pharmaceutical intends to raise up to 968 million yuan for various projects [51]

Group 1 - The core point of the article is that Shanghai Jingxing Industrial Investment Co., Ltd. plans to reduce its stake in Shapuaisi, holding approximately 12.98 million shares, which is about 3.45% of the total share capital, due to funding needs [1] - The planned reduction will occur in two phases: up to approximately 3.76 million shares (1% of total share capital) through centralized bidding from October 10, 2025, to January 9, 2026, and up to approximately 7.52 million shares (2% of total share capital) through block trading during the same period [1] - The total number of shares Shanghai Jingxing plans to reduce is up to approximately 11.28 million shares, which is about 3% of the total share capital [1] Group 2 - For the fiscal year 2024, Shapuaisi's revenue composition is as follows: pharmaceutical industry accounts for 65.74%, diagnostic services for 31.81%, and other businesses for 2.45% [1] - As of the report date, Shapuaisi's market capitalization is 2.9 billion yuan [1]

证券代码：603168 证券简称：莎普爱思 公告编号：临 2025-057 浙江莎普爱思药业股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东持股的基本情况： 截至 2025 年 9 月 26 日，上海景兴实业投资有限公司（以下简称"上海景兴"） 持有莎普爱思无限售条件流通股 12,982,726 股，占莎普爱思总股本的 3.4535%。 减持计划的主要内容 上海景兴因资金需求，计划自本公告披露之日起 3 个交易日后的 3 个月内， 即 2025 年 10 月 10 日至 2026 年 1 月 9 日，通过集中竞价交易方式减持的股份 数量不超过 3,759,250 股，即不超过公司总股本的 1.0000%；自公告披露之日起 3 个交易日后至 2026 年 1 月 9 日，通过大宗交易方式减持的股份数量不超过 7,518,500 股，即不超过公司总股本的 2.0000%。上海景兴计划减持数量合计不 超过 11,277,750 股，即不超过公司总股本的 3.0000% ...

格隆汇9月26日丨莎普爱思(603168.SH)公布，上海景兴因资金需求，计划自本公告披露之日起3个交易 日后的3个月内，即2025年10月10日至2026年1月9日，通过集中竞价交易方式减持的股份数量不超过 375.93万股，即不超过公司总股本的1.0000%；自公告披露之日起3个交易日后至2026年1月9日，通过大 宗交易方式减持的股份数量不超过751.85万股，即不超过公司总股本的2.0000%。上海景兴计划减持数 量合计不超过1127.78万股，即不超过公司总股本的3.0000%。 ...

莎普爱思（603168）(603168.SH)发布公告，上海景兴因资金需求，计划自公告披露之日起3个交易日后 的3个月内，即2025年10月10日至2026年1月9日，减持公司股份数量合计不超过1127.78万股，即不超过 公司总股本的3%。 ...

莎普爱思公告，股东上海景兴因个人资金需求，拟自2025年10月10日至2026年1月9日，通过集中竞价和 大宗交易方式合计减持不超过1127.78万股，合计不超过公司总股本的3.0000%。其中，集中竞价方式减 持不超过375.93万股，占1.0000%；大宗交易方式减持不超过751.85万股，占2.0000%。截至2025年9月 26日，上海景兴持股1298.27万股，占3.4535%。 ...

莎普爱思(603168.SH)发布公告，上海景兴因资金需求，计划自公告披露之日起3个交易日后的3个月 内，即2025年10月10日至2026年1月9日，减持公司股份数量合计不超过1127.78万股，即不超过公司总 股本的3%。 ...

Core Viewpoint - As of September 25, a total of 126 stocks in the Shanghai and Shenzhen markets have experienced net buying from major funds for five consecutive days or more, indicating strong investor interest in these stocks [1] Group 1: Stocks with Significant Net Buying - The stock with the longest consecutive net buying days is Shandong Publishing, which has seen net buying for 16 consecutive trading days [1] - Other notable stocks with significant net buying days include Dashengda, Guangming Meat, Songlin Technology, Liuhua Co., Tianlong Co., Zhongnan Media, China Merchants Port, and Shapuaisi [1]

Core Viewpoint - Zhejiang Shapuaisi Pharmaceutical Co., Ltd. announced the postponement of the investment project for the "Phase II Construction Project of Taizhou Women's and Children's Hospital Co., Ltd." to September 30, 2026, due to the cautious implementation of the project and the need to adjust the investment pace [6][9]. Group 1: Board Meeting - The sixth board meeting of Zhejiang Shapuaisi was held on September 24, 2025, with all nine directors present, and the meeting was deemed legal and effective [2][5]. - The board approved the proposal to waive the notification period for the meeting [3]. - The board also approved the proposal regarding the postponement of the fundraising project [3][11]. Group 2: Fundraising Project Details - The company raised a total of approximately RMB 317.99 million through a non-public stock issuance, with a net amount of RMB 308.24 million after deducting various fees [7]. - As of June 30, 2025, the company had used RMB 309.13 million of the raised funds [8]. - The remaining uninvested portion of the project will be funded by the company’s own funds [9][12]. Group 3: Reasons for Postponement - The postponement of the project is attributed to the company's cautious approach in managing its operations and overall fund usage, leading to a slower investment pace [9]. - The decision to extend the project timeline aims to enhance the efficiency of fund utilization [9]. Group 4: Compliance and Opinions - The postponement was reviewed and approved by the board and the audit committee, complying with relevant regulations [11][12]. - The sponsor institution, Shenwan Hongyuan Securities, confirmed that the necessary procedures were followed and had no objections to the postponement [12].

证券日报网讯 9月24日晚间，莎普爱思发布公告称，公司于2025年9月24日召开第六届审计委员会第六 次会议及第六届董事会第十次会议，审议通过了《关于募投项目延期的议案》，同意将非公开发行股票 募投项目"泰州市妇女儿童医院有限公司医院二期建设项目"达到预定可使用状态日期的时间延期至2026 年9月30日。 （编辑 楚丽君） ...